Press Releases

All Releases
View Summary Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval
Aug 11, 2014
PDF 18.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results
Aug 11, 2014
PDF 22.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call
Aug 4, 2014
PDF 14.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
Jun 25, 2014
PDF 25.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121
Jun 19, 2014
PDF 20.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
Jun 17, 2014
PDF 20.4 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting
Jun 2, 2014
PDF 22.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers
Jun 2, 2014
PDF 120.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
May 27, 2014
PDF 15.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014
May 22, 2014
PDF 25.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
May 7, 2014
PDF 13.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports First Quarter 2014 Financial Results
May 1, 2014
PDF 25.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
May 1, 2014
PDF 19.7 KB Add to Briefcase
View Summary Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398
Apr 8, 2014
PDF 21.2 KB Add to Briefcase
View Summary Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting
Mar 31, 2014
PDF 18.4 KB Add to Briefcase
View Summary Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results
Feb 27, 2014
PDF 24.9 KB Add to Briefcase
View Summary Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference
Feb 24, 2014
PDF 13.7 KB Add to Briefcase
View Summary Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call
Feb 20, 2014
PDF 14.6 KB Add to Briefcase
View Summary Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
Feb 18, 2014
PDF 17.7 KB Add to Briefcase
View Summary Merrimack Initiates Phase 1 Clinical Study of MM-398 in Combination With Cyclophosphamide for Pediatric Solid Tumors
Jan 23, 2014
PDF 20.2 KB Add to Briefcase
Showing 1-20 of 130 Page: 1 2 3 4 5 ... 7  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
6.98

Change:
- 0.05

Day High:
7.04

Day Low:
6.83

Volume:
933,000

4:00 PM ET on Aug 29, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools